Statement: There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.
Primary_evidence: Outcome Measurement:    Progression-free Survival (PFS)   Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Kaplan-Meier survival curves will be used. A 95% confidence interval for the median PFS will be calculated. A lower bound greater than 8 months would be strong evidence that Nab-Paclitaxel- bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is superior to paclitaxel and bevacizumab. However, a median PFS of 13 months or greater (regardless of whether the 95% confidence interval for the median extends below 8 months) could also indicate promising results.   Time frame: Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 8 years Results 1:    Arm/Group Title: Tx (Chemo, MoAb, and Enzyme Inhibitor)   Arm/Group Description: INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.   MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity.   paclitaxel albumin-stabilized nanoparticle formulation: Given IV   bevacizumab: Given IV   erlotinib hydrochloride: Given PO   Overall Number of Participants Analyzed: 55   Median (95% Confidence Interval)   Unit of Measure: Months  9.1        (7.2 to 11.1)